Cargando…

Meningococcal Seroepidemiology 1 Year After the PsA-TT Mass Immunization Campaign in Burkina Faso

Background. A group A meningococcal (MenA) conjugate vaccine, PsA-TT (MenAfriVac), was introduced in Burkina Faso via mass campaigns between September and December 2010, targeting the 1- to 29-year-old population. This study describes specific antibody titers in the general population 11 months late...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tall, Haoua, Yaro, Seydou, Kpoda, Hervé B. N., Ouangraoua, Soumeya, Trotter, Caroline L., Njanpop Lafourcade, Berthe-Marie, Findlow, Helen, Bai, Xilian, Martin, Catherine, Nwakamma, Ikenna, Ouedraogo, Jean Bosco, Gessner, Bradford D., Borrow, Ray, Mueller, Judith E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2015
Materias:	The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639492/ https://www.ncbi.nlm.nih.gov/pubmed/26553686 http://dx.doi.org/10.1093/cid/civ519

Ejemplares similares

Population-Level Persistence of Immunity 2 Years After the PsA-TT Mass-Vaccination Campaign in Mali
por: Basta, Nicole E., et al.
Publicado: (2015)

Neisseria meningitidis Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12–23 Months Following Meningococcal Vaccination
por: Holme, Daniel, et al.
Publicado: (2015)

Higher Tetanus Toxoid Immunity 2 Years After PsA-TT Introduction in Mali
por: Basta, Nicole E., et al.
Publicado: (2015)

Influence of Age on Antibody Response and Persistence Following Immunization With MenAfriVac
por: Tang, Yuxiao, et al.
Publicado: (2015)

Antibody Persistence 1–5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12–23 Months of Age
por: Tapia, Milagritos D., et al.
Publicado: (2015)

MenAfriVac as an Antitetanus Vaccine
por: Borrow, Ray, et al.
Publicado: (2015)

Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2–29 Years
por: Diallo, Aldiouma, et al.
Publicado: (2015)

Documenting the Results of a Successful Partnership: A New Meningococcal Vaccine for Africa
por: Okwo-Bele, Jean-Marie, et al.
Publicado: (2015)

Costs of Neisseria meningitidis Group A Disease and Economic Impact of Vaccination in Burkina Faso
por: Colombini, Anaïs, et al.
Publicado: (2015)

Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt
por: Karachaliou, Andromachi, et al.
Publicado: (2015)

A Vaccine Meets Its Promise: Success in Controlling Epidemic Meningitis in Sub-Saharan Africa
por: Sambo, Luis, et al.
Publicado: (2015)

Regulatory Pathways That Facilitated Timely Registration of a New Group A Meningococcal Conjugate Vaccine for Africa's Meningitis Belt Countries
por: Dellepiane, Nora, et al.
Publicado: (2015)

Communication Challenges During the Development and Introduction of a New Meningococcal Vaccine in Africa
por: Berlier, Monique, et al.
Publicado: (2015)

Active Surveillance for Adverse Events After a Mass Vaccination Campaign With a Group A Meningococcal Conjugate Vaccine (PsA-TT) in Mali
por: Vannice, Kirsten S., et al.
Publicado: (2015)

Public Health Impact After the Introduction of PsA-TT: The First 4 Years
por: Diomandé, Fabien V. K., et al.
Publicado: (2015)

Challenges and Opportunities While Developing a Group A Meningococcal Conjugate Vaccine Within a Product Development Partnership: A Manufacturer's Perspective From the Serum Institute of India
por: Kulkarni, Prasad S., et al.
Publicado: (2015)

Safety Monitoring in Group A Meningococcal Conjugate Vaccine Trials: Description, Challenges, and Lessons
por: Enwere, Godwin C., et al.
Publicado: (2015)

Introduction and Rollout of a New Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 2010–2014
por: Djingarey, Mamoudou H., et al.
Publicado: (2015)

From Epidemic Meningitis Vaccines for Africa to the Meningitis Vaccine Project
por: Aguado, M. Teresa, et al.
Publicado: (2015)

The Evolution of the Meningitis Vaccine Project
por: Tiffay, Kathleen, et al.
Publicado: (2015)

Technical Development of a New Meningococcal Conjugate Vaccine
por: Frasch, Carl E., et al.
Publicado: (2015)

Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials
por: Idoko, Olubukola T., et al.
Publicado: (2015)

Meningococcal Meningitis Surveillance in the African Meningitis Belt, 2004–2013
por: Lingani, Clément, et al.
Publicado: (2015)

Ethical Challenges and Lessons Learned During the Clinical Development of a Group A Meningococcal Conjugate Vaccine
por: Martellet, Lionel, et al.
Publicado: (2015)

Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010–2013
por: Diomandé, Fabien V. K., et al.
Publicado: (2015)

Immunogenicity of Yellow Fever Vaccine Coadministered With MenAfriVac in Healthy Infants in Ghana and Mali
por: Roy Chowdhury, Panchali, et al.
Publicado: (2015)

The Safety of PsA-TT in Pregnancy: An Assessment Performed Within the Navrongo Health and Demographic Surveillance Site in Ghana
por: Wak, George, et al.
Publicado: (2015)

A Phase 3, Double-Blind, Randomized, Active Controlled Study to Evaluate the Safety of MenAfriVac in Healthy Malians
por: Tapia, Milagritos D., et al.
Publicado: (2015)

Risk Assessment and Meningococcal A Conjugate Vaccine Introduction in Africa: The District Prioritization Tool
por: Cibrelus, Laurence, et al.
Publicado: (2015)

Pneumococcal Carriage in Burkina Faso After 13-Valent Pneumococcal Conjugate Vaccine Introduction: Results From 2 Cross-sectional Population-Based Surveys
por: Kaboré, Lassané, et al.
Publicado: (2021)

Implications of Differential Age Distribution of Disease-Associated Meningococcal Lineages for Vaccine Development
por: Brehony, Carina, et al.
Publicado: (2014)

Characteristics of patients receiving allergy vaccination: to which extent do socio-economic factors play a role?
por: Petersen, Karin Dam, et al.
Publicado: (2011)

Process of Assay Selection and Optimization for the Study of Case and Control Samples from a Phase IIb Efficacy Trial of a Candidate Tuberculosis Vaccine, MVA85A
por: Harris, Stephanie A., et al.
Publicado: (2014)

Comparative Efficacy of Feline Leukemia Virus (FeLV) Inactivated Whole-Virus Vaccine and Canarypox Virus-Vectored Vaccine during Virulent FeLV Challenge and Immunosuppression
por: Patel, M., et al.
Publicado: (2015)

Characterization of T-Cell Responses to Conserved Regions of the HIV-1 Proteome in BALB/c Mice
por: Ondondo, Beatrice, et al.
Publicado: (2014)

Toll-Like Receptor Activation by Generalized Modules for Membrane Antigens from Lipid A Mutants of Salmonella enterica Serovars Typhimurium and Enteritidis
por: Rossi, Omar, et al.
Publicado: (2016)

Correlates of Protection against Influenza in the Elderly: Results from an Influenza Vaccine Efficacy Trial
por: Dunning, Andrew J., et al.
Publicado: (2016)

Evaluation of the Immunogenicity of Mycobacterium bovis BCG Delivered by Aerosol to the Lungs of Macaques
por: White, A. D., et al.
Publicado: (2015)

The Carbomer-Lecithin Adjuvant Adjuplex Has Potent Immunoactivating Properties and Elicits Protective Adaptive Immunity against Influenza Virus Challenge in Mice
por: Wegmann, Frank, et al.
Publicado: (2015)

Auto-Assembling Detoxified Staphylococcus aureus Alpha-Hemolysin Mimicking the Wild-Type Cytolytic Toxin
por: Fiaschi, Luigi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_75i4kr7mhoimg8dji2o26kacd4